Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lumara Health

- PMLiVE

GSK buys vaccine specialist GlycoVaxyn for $190m

Acquisition will expand GSK’s early vaccines pipeline

- PMLiVE

Pfizer’s bid for Hospira could lead to break-up

Questions posed whether $15bn bid will be profitable for the firm

- PMLiVE

Actavis claims top UK generics spot with Auden Mckenzie buy

Firm claims the deal will make it the UK’s third-largest pharma manufacturer

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

- PMLiVE

Merck stumps up $375m for cancer firm OncoEthix

Follows $8.4bn deal to buy Cubist

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

Bristol-Myers Squibb (BMS) building

BMS takes option to buy fibrosis firm Galecto

The Swedish biotech has a pulmonary fibrosis candidate in early-stage testing

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

Actavis buys infectious disease specialist Durata

Will acquire US-approved Dalvance as part of the deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links